IM29L Anti-PAI-1 (Ab-1) Mouse mAb (2)

IM29L
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability

      Overview

      Replacement Information

      Key Specifications Table

      Species ReactivityHostAntibody Type
      H M Monoclonal Antibody

      Pricing & Availability

      Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
      IM29L-100UG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Plastic ampoule 100 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewRecognizes both active and latent forms of the ~50 kDa PAI-1 protein in conditioned media from dexamethasone-treated HT-1080 cells. Sold under license of U.S. Patent 5,422,245.
          Catalogue NumberIM29L
          Brand Family Calbiochem®
          SynonymsAnti-Plasminogen Activator Inhibitor-1
          References
          ReferencesJanicke, F., et al. 1994. Cancer Research. 54, 2527.
          Lawrence, D. A., et al. 1994. J. Biol. Chem. 269, 15223.
          Nagayama, M., et al. 1994. Cancer 73, 1398.
          Petersen, H., et al. 1994. Cancer Res. 54, 120.
          Keijer, J., et al. 1991. Blood 78, 401.
          Blasi, F. and Verde, P., 1990. in Seminars in Cancer Biol. Vol. 1, 153.
          Declerck, P. J. and Collen, D., 1990. Thrombosis Res. Supplement X 3.
          Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis. 55, 206.
          Product Information
          DeclarationSold under license of U.S. Patent 5,422,245.
          FormLyophilized
          FormulationLyophilized from a volatile buffer, 100 µg BSA.
          Positive controlConditioned media from dexamethasone-treated (1 µM) HT-1080 cells
          PreservativeNone
          Applications
          Application ReferencesImmunoprecipitation Keijer, J., et al. 1991. Blood 78, 401 Original Clone, Immunocytochemistry, Neutralization Studies Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis. 55, 206.
          Key Applications Neutralization Studies
          Immunoblotting (Western Blotting)
          Immunocytochemistry
          Immunoprecipitation
          Application NotesImmunoblotting (1 µg/ml)
          Immunoprecipitation (see application references)
          Immunocytochemistry (see application references
          Neutralization Studies (see application references)
          Application CommentsAntibody should be titrated for optimal results in individual systems.
          Biological Information
          Immunogenpartially purified PAI-1 from conditioned medium of dexamethasone-treated HT1080 human cells
          ImmunogenHuman
          Clone2
          HostMouse
          IsotypeIgG₁
          Species Reactivity
          • Human
          Antibody TypeMonoclonal Antibody
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Do not freeze Ok to freeze
          Special InstructionsWe recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least 2 h.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Anti-PAI-1 (Ab-1) Mouse mAb (2) SDS

          Title

          Safety Data Sheet (SDS) 

          Anti-PAI-1 (Ab-1) Mouse mAb (2) Certificates of Analysis

          TitleLot Number
          IM29L

          References

          Reference overview
          Janicke, F., et al. 1994. Cancer Research. 54, 2527.
          Lawrence, D. A., et al. 1994. J. Biol. Chem. 269, 15223.
          Nagayama, M., et al. 1994. Cancer 73, 1398.
          Petersen, H., et al. 1994. Cancer Res. 54, 120.
          Keijer, J., et al. 1991. Blood 78, 401.
          Blasi, F. and Verde, P., 1990. in Seminars in Cancer Biol. Vol. 1, 153.
          Declerck, P. J. and Collen, D., 1990. Thrombosis Res. Supplement X 3.
          Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis. 55, 206.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision28-September-2007 JSW
          SynonymsAnti-Plasminogen Activator Inhibitor-1
          ApplicationImmunoblotting (1 µg/ml)
          Immunoprecipitation (see application references)
          Immunocytochemistry (see application references
          Neutralization Studies (see application references)
          DescriptionPurified mouse monoclonal antibody (see application references). Recognizes both active and latent forms of the ~50 kDa PAI-1 protein.
          BackgroundPlasminogen activator inhibitor 1 (PAI-1) is a secreted glycoprotein of approximately 50 kDa, which functions as the primary regulator of uPA and tPA activity. PAI-1 and the related inhibitor, PAI-2, are members of the serine proteinase inhibitor (serpin) gene superfamily. PAI-1 is produced by a variety of cell types and is present in normal human plasma. It exists as two conformationally distinct forms, latent and active. The active form binds to uPA in a 1:1 complex resulting in the inhibition of proteolytic activity. Active PAI-1 rapidly converts to the latent form but can be stabilized in the active conformation by binding to the cell adhesion glycoprotein, vitronectin. Latent PAI-1 can be activated in vitro by exposure to denaturants such as SDS or guanidine. PAI-1 levels are increased in a number of disease states including coronary artery disease, venous thrombosis, obesity and various types of cancer. Recent studies indicate that elevated PAI-1 may be a useful prognostic marker for several types of cancers, particularly breast and lung.
          HostMouse
          Immunogen speciesHuman
          Immunogenpartially purified PAI-1 from conditioned medium of dexamethasone-treated HT1080 human cells
          Clone2
          IsotypeIgG₁
          Specieshuman
          Positive controlConditioned media from dexamethasone-treated (1 µM) HT-1080 cells
          FormLyophilized
          FormulationLyophilized from a volatile buffer, 100 µg BSA.
          PreservativeNone
          CommentsAntibody should be titrated for optimal results in individual systems.
          Storage +2°C to +8°C
          Do Not Freeze Ok to freeze
          Special InstructionsWe recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least 2 h.
          Toxicity Standard Handling
          ReferencesJanicke, F., et al. 1994. Cancer Research. 54, 2527.
          Lawrence, D. A., et al. 1994. J. Biol. Chem. 269, 15223.
          Nagayama, M., et al. 1994. Cancer 73, 1398.
          Petersen, H., et al. 1994. Cancer Res. 54, 120.
          Keijer, J., et al. 1991. Blood 78, 401.
          Blasi, F. and Verde, P., 1990. in Seminars in Cancer Biol. Vol. 1, 153.
          Declerck, P. J. and Collen, D., 1990. Thrombosis Res. Supplement X 3.
          Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis. 55, 206.
          Application referencesImmunoprecipitation Keijer, J., et al. 1991. Blood 78, 401 Original Clone, Immunocytochemistry, Neutralization Studies Nielsen, L. S., et al. 1986. Thrombosis and Haemostasis. 55, 206.